HemaSphere (Jun 2022)

P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY

  • A. Tivey,
  • R. Shotton,
  • T. A. Eyre,
  • D. Lewis,
  • N. Crosbie,
  • E. Nga,
  • R. Guerrero Camacho,
  • W. Swe,
  • H. Marr,
  • C. Rees,
  • S. Moule,
  • T. Sutton,
  • D. Wrench,
  • N. Thomas,
  • M. Wilson,
  • J. Bailey,
  • M. Prahladan,
  • A. Hodson,
  • M. Koppana,
  • S. Smith,
  • S. Jones,
  • F. Miall,
  • J. Norman,
  • E. Davies,
  • C. Hildyard,
  • L. Lowry,
  • S. Paneesha,
  • I. Qureshi,
  • A. Beech,
  • C. Bedford,
  • A. Everden,
  • D. Tucker,
  • J. Wright,
  • J. Goddard,
  • T. Nicholson,
  • J. Wilson,
  • A. Lord,
  • B. Jackson,
  • M. Flont,
  • A. Gibb,
  • K. Linton

DOI
https://doi.org/10.1097/01.HS9.0000847432.95668.eb
Journal volume & issue
Vol. 6
pp. 1031 – 1032

Abstract

Read online

No abstracts available.